Vidac Pharma Holding Plc | Finanzwire

Basculer en Français

8396	Companies
122097	Keywords
60577	Articles
65553	Press releases

Headlines Articles Press releases Vidac Pharma Holding Plc

Home
Companies
Vidac Pharma Holding Plc

BRIEF

published on 11/20/2024 at 09:21, 1 month 1 day ago

Vidac Pharma Granted Key Patent by USPTO

Clinical Trials Cancer Treatment USPTO Patent Vidac Pharma Hexokinase-2
PRESS RELEASE

published on 11/20/2024 at 09:16, 1 month 1 day ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Update report on Vidac Pharma Holding Plc by Sphene Capital GmbH highlighting the significant patent protection granted by the USPTO for its cancer products, leading to a Buy recommendation with a target price of EUR 4.90

Investment Recommendation USPTO Patent Sphene Capital Vidac Pharma Cancer Products
BRIEF

published on 07/29/2024 at 12:31, 4 months 23 days ago

Sphene Capital Reaffirms 'Buy' Rating for Vidac Pharma Holding

BUY Rating Cancer Therapy Sphene Capital Vidac Pharma VDA-1275
PRESS RELEASE

published on 07/29/2024 at 12:26, 4 months 23 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Update report by Sphene Capital GmbH highlights promising results of VDA-1275 study by Vidac Pharma Holding Plc in cancer treatment. Buy recommendation maintained with EUR 4.90 target price

Cancer Treatment Sphene Capital GmbH Vidac Pharma Holding VDA-1275 Study EUR 4.90 Target Price
BRIEF

published on 06/12/2024 at 14:41, 6 months 9 days ago

Vidac Pharma Holding Plc: Research Initiation by Sphene Capital GmbH with a Buy Rating

Oncology BUY Rating Biopharmaceutical Clinical-stage Vidac Pharma
PRESS RELEASE

published on 06/12/2024 at 14:36, 6 months 9 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Sphene Capital initiates coverage on Vidac Pharma Holding Plc with a Buy rating and a price target of EUR 4.90. Vidac Pharma focuses on reversing cancer cell metabolism for oncology treatments

BUY Rating Sphene Capital GmbH Vidac Pharma Holding Plc Cancer Cell Metabolism Oncology Treatments

Accesswire

Published on 12/21/2024 at 01:30, 18 hours 1 minute ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 18 hours 1 minute ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 26 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 31 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 20 hours 1 minute ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 12/21/2024 at 00:51, 18 hours 40 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 46 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

Les Echos

Published on 12/21/2024 at 12:17, 7 hours 13 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days 1 hour ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE